This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
p53 Monoclonal Antibody (DO-7), Biotin
catalog :
MA5-12554
quantity :
500 µL
price :
US 456.00
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
DO-7
reactivity :
human, mouse
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
citations: 132
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; 1:500; loading ...; tbl 2
Jang M, Kim S, Hwang D, Kim W, Lim S, Kim W, et al. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. J Korean Med Sci. 2017;32:38-46 pubmed publisher
  • immunoprecipitation; human
  • western blot; human
Cubillos Rojas M, Amair Pinedo F, Peiró Jordán R, Bartrons R, Ventura F, Rosa J. The E3 ubiquitin protein ligase HERC2 modulates the activity of tumor protein p53 by regulating its oligomerization. J Biol Chem. 2014;289:14782-95 pubmed publisher
  • immunohistochemistry; human
Akay O, Aras B, Isiksoy S, Toprak C, Mutlu F, Artan S, et al. BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients. Cancer Genet. 2014;207:87-93 pubmed publisher
  • immunohistochemistry; human; 1:1000
Stelloo E, Nout R, Naves L, Ter Haar N, Creutzberg C, Smit V, et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol. 2014;133:197-204 pubmed publisher
  • immunohistochemistry; human; 1:250
Mingels M, van Ham M, de Kievit I, Snijders M, van Tilborg A, Bulten J, et al. Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. Mod Pathol. 2014;27:1002-13 pubmed publisher
  • immunohistochemistry; human; 1:200
  • western blot; human; 1:200
Zhao Z, Lin L, Liang A, Li H, Zhu Y. UNC5H4-induced apoptosis in non-small cell lung cancer is not dependent on p53 status only. Oncol Lett. 2013;6:1363-1369 pubmed
  • immunohistochemistry; human; 1:500
Baumgarten P, Harter P, Tonjes M, Capper D, Blank A, Sahm F, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40:205-16 pubmed publisher
  • immunohistochemistry; human; 1:50
Bakry O, Hammam M, Abdel Wahed M. Vitiligo: is it grace or curse?. Acta Dermatovenerol Croat. 2013;21:71-9 pubmed
  • immunohistochemistry; human; 1:1000
Sarasqueta A, Forte G, Corver W, de Miranda N, Ruano D, van Eijk R, et al. Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer. 2013;13:277 pubmed publisher
  • immunohistochemistry; human; 1:1000
Lee S, Kim H, Kim W, Han H, Lim S, Kim W, et al. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern. Pathol Int. 2013;63:252-9 pubmed publisher
  • immunohistochemistry; human
Bosse T, Ter Haar N, Seeber L, v Diest P, Hes F, Vasen H, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013;26:1525-35 pubmed publisher
  • immunohistochemistry; human
Malhotra P, Anwar M, Nanda N, Kochhar R, Wig J, Vaiphei K, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol. 2013;34:1901-11 pubmed publisher
  • immunohistochemistry; human
Gurzu S, Szentirmay Z, Toth E, Bara T, Jung I. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition. PLoS ONE. 2013;8:e57699 pubmed publisher
  • immunohistochemistry; human; 1:100
Rosati A, Poliani P, Todeschini A, Cominelli M, Medicina D, Cenzato M, et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol. 2013;15:618-25 pubmed publisher
  • immunocytochemistry; human; 1:500
  • immunohistochemistry; human; 1:500
Harter P, Dützmann S, Drott U, Zachskorn C, Hattingen E, Capper D, et al. Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model. Neuropathology. 2013;33:515-25 pubmed publisher
  • western blot; human
Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick Silverman L, et al. Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. PLoS ONE. 2013;8:e55145 pubmed publisher
  • immunohistochemistry; human; 1:100
Ko E, Lee B, Kim Y, Lee E, Cho E, Han J, et al. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clin Cancer Res. 2013;19:1204-12 pubmed publisher
  • immunohistochemistry; human; 1:30
Lee E, Lee B, Ko E, Kim Y, Han J, Shim Y, et al. Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma. Cancer. 2013;119:1752-60 pubmed publisher
  • immunohistochemistry; human; 1:50
Bakry O, Hammam M, Wahed M. Immunohistochemical detection of P53 and Mdm2 in vitiligo. Indian Dermatol Online J. 2012;3:171-6 pubmed publisher
  • immunohistochemistry; human
Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, et al. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell. 2012;22:404-15 pubmed publisher
  • immunohistochemistry; human
Vallen M, Massuger L, ten Dam G, Bulten J, van Kuppevelt T. Highly sulfated chondroitin sulfates, a novel class of prognostic biomarkers in ovarian cancer tissue. Gynecol Oncol. 2012;127:202-9 pubmed publisher
  • immunohistochemistry; human; 1:50
Ni H, Piao Y, Lu D, Fu Y, Ma X, Zhang X. Chordoid glioma of the third ventricle: four cases including one case with papillary features. Neuropathology. 2013;33:134-9 pubmed publisher
  • western blot; mouse; 1:500
Hardee M, Marciscano A, Medina Ramirez C, Zagzag D, Narayana A, Lonning S, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-?. Cancer Res. 2012;72:4119-29 pubmed publisher
  • western blot; human
Roh J, Ko J, Moon S, Ryu C, Choi J, Koch W. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett. 2012;325:35-41 pubmed publisher
  • immunohistochemistry; human; 1:2000
Smits A, Jin Z, Elsir T, Pedder H, Nister M, Alafuzoff I, et al. GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. PLoS ONE. 2012;7:e37041 pubmed publisher
  • immunohistochemistry; human; 1:1000
Nout R, Bosse T, Creutzberg C, Jürgenliemk Schulz I, Jobsen J, Lutgens L, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/?-catenin and P53 pathway activation. Gynecol Oncol. 2012;126:466-73 pubmed publisher
  • western blot; human; 1:1000
Zimmermann M, Arachchige Don A, Donaldson M, Dallapiazza R, Cowan C, Horne M. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin. J Biol Chem. 2012;287:22838-53 pubmed publisher
  • western blot; human
Richardson E, Stockwell S, Li H, Aherne W, Cuomo M, Mittnacht S. Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response. PLoS ONE. 2012;7:e31627 pubmed publisher
  • immunohistochemistry; human; 1:250
Roelofsen T, van Kempen L, van der Laak J, van Ham M, Bulten J, Massuger L. Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion?. Int J Gynecol Cancer. 2012;22:457-64 pubmed publisher
  • immunohistochemistry; human; 1:1500
Ko Y, Hwang T, Han H, Lim S, Kim W, Oh S. Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation. Pathol Int. 2012;62:43-8 pubmed publisher
  • immunohistochemistry; human
Aydin F, Levent Y, Nilgun S, Pancar Y, Yasar T. Implications of bax, fas, and p53 in the pathogenesis of early-stage mycosis fungoides and alterations in expression following photochemotherapy. Indian J Dermatol. 2011;56:501-4 pubmed publisher
  • immunohistochemistry; human; 1:300
Van der Vorst S, Dekairelle A, Weynand B, Hamoir M, Gala J. Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma. Head Neck. 2012;34:1542-50 pubmed publisher
  • immunohistochemistry; human
Rosztoczy A, Izbeki F, Nemeth I, Dulic S, Vadászi K, Roka R, et al. Detailed esophageal function and morphological analysis shows high prevalence of gastroesophageal reflux disease and Barrett's esophagus in patients with cervical inlet patch. Dis Esophagus. 2012;25:498-504 pubmed publisher
  • immunohistochemistry; human
Manganoni A, Rossi M, Sala R, Venturini M, Sereni E, Ungari M, et al. Dermoscopic, histological and immunohistochemical evaluation of cancerous features in acquired melanocytic nevi that have been repeatedly exposed to UVA or UVB. Exp Dermatol. 2012;21:86-90 pubmed publisher
  • immunohistochemistry; human
Nemeth I, Rosztoczy A, Izbeki F, Roka R, Gecse K, Sukosd F, et al. A renewed insight into Barrett's esophagus: comparative histopathological analysis of esophageal columnar metaplasia. Dis Esophagus. 2012;25:395-402 pubmed publisher
  • immunohistochemistry; human; 1:2000
Heusinkveld M, Goedemans R, Briet R, Gelderblom H, Nortier J, Gorter A, et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer. 2012;131:E74-85 pubmed publisher
  • immunohistochemistry; human; 1:200
Wolfárd A, Paszt A, Szentpali K, Hideghéthy K, Uhercsak G, Nemeth I, et al. Efficacy and drawbacks of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the thoracic esophagus. Hepatogastroenterology. 2011;58:1214-9 pubmed publisher
  • immunohistochemistry; human
Arik D, Kulacoglu S. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters. Turk Patoloji Derg. 2011;27:38-45 pubmed
  • immunohistochemistry; human; 1:300
Ege C, Akbulut M, Zekioglu O, Ozdemir N. Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival. Arch Gynecol Obstet. 2011;284:1231-9 pubmed publisher
  • western blot; human
Halperin R, Stafford P, Johnston S. Exploring antibody recognition of sequence space through random-sequence peptide microarrays. Mol Cell Proteomics. 2011;10:M110.000786 pubmed publisher
  • immunohistochemistry; human; 1:50
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010;28:5188-96 pubmed publisher
  • immunohistochemistry; human; 1:500
Radotra B, Apostolopoulos V, Sandison A, Hatfield E, Mendoza N, Moss J, et al. Primary sellar neuroblastoma presenting with syndrome of inappropriate secretion of anti-diuretic hormone. Endocr Pathol. 2010;21:266-73 pubmed publisher
  • western blot; human
Tarjan G, Haines G, Vesper B, Xue J, Altman M, Yarmolyuk Y, et al. Part II. Initial molecular and cellular characterization of high nitric oxide-adapted human tongue squamous cell carcinoma cell lines. Tumour Biol. 2011;32:87-98 pubmed publisher
  • immunohistochemistry; human; 1:100
Kosemehmetoglu K, Akpinar E, Sokmensuer C, Hamaloglu E. Papillary carcinoma with diffuse papillomatosis of gallbladder and cystic duct. Ann Diagn Pathol. 2011;15:140-4 pubmed publisher
  • immunohistochemistry; human; 1:150
Angiero F, Gatta L, Seramondi R, Berenzi A, Benetti A, Magistro S, et al. Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res. 2010;30:3435-40 pubmed
  • immunohistochemistry; human; 1:25
Giordano G, D Adda T, Brigati F, Lombardi M, Raboni S. A Unique case of primary squamous carcinoma of the salpinx associated with serous carcinoma of the omentum: a pathological and molecular study. Int J Gynecol Pathol. 2010;29:533-8 pubmed publisher
  • immunohistochemistry; human; 1:1000
van der Avoort I, van de Nieuwenhof H, Otte Holler I, Nirmala E, Bulten J, Massuger L, et al. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva. Hum Pathol. 2010;41:1475-85 pubmed publisher
  • immunohistochemistry; human; 1:150
Safadi R, Al Jaber S, Hammad H, Hamasha A. Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study. Arch Oral Biol. 2010;55:454-61 pubmed publisher
  • immunohistochemistry; human; 1:100
Bircan A, Bircan S, Kapucuoglu N, Songur N, Ozturk O, Akkaya A. Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters. Pathol Oncol Res. 2010;16:553-61 pubmed publisher
  • western blot; human; 1:400
Yu F, Hao X, Zhao H, Ge C, Yao M, Yang S, et al. Delta-like 1 contributes to cell growth by increasing the interferon-inducible protein 16 expression in hepatocellular carcinoma. Liver Int. 2010;30:703-14 pubmed publisher
  • western blot; human; 1:200
Yang L, Xu H, Han Y, Li Q, Liu Y, Zhao Y, et al. Axin downregulates TCF-4 transcription via beta-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells. Mol Cancer. 2010;9:25 pubmed publisher
  • immunohistochemistry; human; 1:50
Sarafoleanu D, Postelnicu V, Iosif C, Manea C, Sarafoleanu C. The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. J Med Life. 2009;2:219-26 pubmed
  • immunohistochemistry; human; 1:100
Kim H, Park Y, Lee J, Ahn J, Kim J, Shim Y, et al. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 2010;116:676-85 pubmed publisher
  • immunohistochemistry; human; 1:100
Angiero F, Farronato G, Dessy E, Magistro S, Seramondi R, Farronato D, et al. Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. Anticancer Res. 2009;29:3983-7 pubmed
  • western blot; human
de Frias M, Iglesias Serret D, Cosialls A, Coll Mulet L, Santidrian A, González Gironès D, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009;94:1698-707 pubmed publisher
  • immunohistochemistry; human; 1:200
Han Y, Wang Y, Xu H, Yang L, Wei Q, Liu Y, et al. X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression. Int J Radiat Oncol Biol Phys. 2009;75:518-26 pubmed publisher
  • immunohistochemistry; human; 1:50
Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist K. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol. 2009;183:3616-24 pubmed publisher
  • immunohistochemistry; human; 1:200
Sakiz D, Turkmenoglu T, Kabukcuoglu F. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract. 2009;205:589-94 pubmed publisher
  • immunohistochemistry; human; 1:1000
Nielsen M, de Miranda N, van Puijenbroek M, Jordanova E, Middeldorp A, van Wezel T, et al. Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer. 2009;9:184 pubmed publisher
  • western blot; human
Molenaar J, Ebus M, Geerts D, Koster J, Lamers F, Valentijn L, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A. 2009;106:12968-73 pubmed publisher
  • immunohistochemistry; human; 1:50
Jung I, Gurzu S, Raica M, Cimpean A, Szentirmay Z. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis. Rom J Morphol Embryol. 2009;50:239-43 pubmed
  • immunohistochemistry; human
Ozger H, Eralp L, Atalar A, Toker B, Esberk Ateş L, Sungur M, et al. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis]. Acta Orthop Traumatol Turc. 2009;43:28-34 pubmed publisher
  • western blot; mouse
Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci U S A. 2009;106:3431-6 pubmed publisher
  • immunohistochemistry; human
Thant A, Wu Y, Lee J, Mishra D, Garcia H, Koeffler H, et al. Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res. 2008;28:3579-92 pubmed
  • immunohistochemistry; human; 1:150
Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res. 2008;28:2535-9 pubmed
  • immunohistochemistry; human; 1:100
Alkim C, Savas B, Ensari A, Alkim H, Dagli U, Parlak E, et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci. 2009;54:1979-84 pubmed publisher
  • immunohistochemistry; human
Kresty L, Mallery S, Knobloch T, Li J, Lloyd M, Casto B, et al. Frequent alterations of p16INK4a and p14ARF in oral proliferative verrucous leukoplakia. Cancer Epidemiol Biomarkers Prev. 2008;17:3179-87 pubmed publisher
  • immunohistochemistry; human
Gurzu S, Jung I, Prantner I, Ember I, Pávai Z, Mezei T. The expression of cytoskeleton regulatory protein Mena in colorectal lesions. Rom J Morphol Embryol. 2008;49:345-9 pubmed
  • immunohistochemistry; human; 1:50
Ceausu M, Curca C, Ardeleanu C, Dermengiu D. Immunophenotypical pleomorphism expression in sudden cardiac death. Rom J Morphol Embryol. 2008;49:315-20 pubmed
  • immunohistochemistry; human; 1:50
Villanacci V, Cestari R, Giulini S, Cengia P, Missale G, Berenzi A, et al. Immunocytochemical assessment of p53 protein to detect malignancy in increased cell-yield brush cytology from the biliopancreatic tree. Dig Dis Sci. 2009;54:789-92 pubmed publisher
  • western blot; human
Hamamoto T, Suzuki K, Yamauchi M, Kodama S, Sasaki H, Watanabe M. p53 status-dependent sensitization of human tumour cells to hyperthermia by plant flavonol. Int J Hyperthermia. 2008;24:415-24 pubmed publisher
  • western blot; human
Turner N, Lord C, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008;27:1368-77 pubmed publisher
  • immunohistochemistry; human
Kaya H, Bozkurt S, Erbarut I, Djamgoz M. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract. 2008;204:367-71 pubmed publisher
  • immunohistochemistry; human; 1:1000
Lips E, van Eijk R, de Graaf E, Doornebosch P, de Miranda N, Oosting J, et al. Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res. 2008;14:772-81 pubmed publisher
  • immunohistochemistry; human
Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064-9 pubmed
  • immunohistochemistry; human; 1:200
Melck A, Masoudi H, Griffith O, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14:3403-11 pubmed
  • immunohistochemistry; human; 1:100
Erdamar S, Ucaryilmaz E, Demir G, Karahasanoglu T, Dogusoy G, Dirican A, et al. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer. World J Gastroenterol. 2007;13:4437-44 pubmed
  • immunohistochemistry; human; 1:50
Kim D. Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer. Yonsei Med J. 2007;48:694-700 pubmed
  • immunohistochemistry; human
Gurzu S, Jung J, Mezei T, Pávai Z. The correlation between the immunostains for p53 and Ki67 with bcl-2 expression and classical prognostic factors in colorectal carcinomas. Rom J Morphol Embryol. 2007;48:95-9 pubmed
  • western blot; mouse
Arany P, Flanders K, DeGraff W, Cook J, Mitchell J, Roberts A. Absence of Smad3 confers radioprotection through modulation of ERK-MAPK in primary dermal fibroblasts. J Dermatol Sci. 2007;48:35-42 pubmed
  • immunohistochemistry; human; 1:25
Giordano G, D Adda T, Gnetti L, Merisio C, Raboni S. Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol. 2007;26:298-304 pubmed
  • immunohistochemistry; human
Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther. 2007;6:1478-82 pubmed
  • western blot; mouse; 1:1000
Ray S, Chatterjee A. Influence of glutathione on the induction of chromosome aberrations, delay in cell cycle kinetics and cell cycle regulator proteins in irradiated mouse bone marrow cells. Int J Radiat Biol. 2007;83:347-54 pubmed
  • immunohistochemistry; human; 1:50
Giordano G, D Adda T, Gnetti L, Merisio C, Gabrielli M, Melpignano M. Villoglandular adenocarcinoma of the cervix: two new cases with morphological and molecular study. Int J Gynecol Pathol. 2007;26:199-204 pubmed
  • immunoprecipitation; human; 2 ug/ml
Kerley Hamilton J, Pike A, Hutchinson J, Freemantle S, Spinella M. The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins. Biochim Biophys Acta. 2007;1769:209-19 pubmed
  • immunohistochemistry; human
Nadasi E, Anga B, Sandor J, Megyesi J, Kelemen D, Mottolese M, et al. Prognostic factors in Hungarian breast cancer patients. Anticancer Res. 2007;27:279-82 pubmed
  • immunohistochemistry; human
Vardar E, Gunlusoy B, Arslan M, Kececi S. Myointimoma of the glans penis. Pathol Int. 2007;57:158-61 pubmed
  • western blot; human; 1:500
Schumacher G, Scheunert S, Rueggeberg A, Bachem M, Nussler A, Spinelli A, et al. A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2006;21:1207-12 pubmed
  • immunohistochemistry; human
Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch. 2006;449:164-70 pubmed
  • immunohistochemistry; human
Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119:1920-6 pubmed
  • immunohistochemistry; human
Bulut S, Uslu H, Ozdemir B, Bulut O. Expression of caspase-3, p53 and Bcl-2 in generalized aggressive periodontitis. Head Face Med. 2006;2:17 pubmed
  • immunohistochemistry; human; 1:50
Ardeleanu C, Ceausu M, Butur G, Grămadă Z, Danaila L, Hălălău F, et al. p53 protein and bcl-2 expression in glioblastomas. Pathological correlations in a comprehensive series. Rom J Morphol Embryol. 2005;46:275-8 pubmed
  • immunohistochemistry; human; 1:50
Lee M, Suh C, Li Z. Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci. 2006;21:309-14 pubmed
  • western blot; human
Coll Mulet L, Iglesias Serret D, Santidrian A, Cosialls A, de Frias M, Castaño E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109-14 pubmed
  • immunohistochemistry; human
Schrier B, Vriesema J, Witjes J, Kiemeney L, Schalken J. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol. 2006;50:76-82 pubmed
  • immunohistochemistry; human; 2 ug/ml
Gao R, Bao H, Yang Q, Cong Q, Song J, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005;93:111-5 pubmed
  • immunohistochemistry; human; 1:100
Yilmazbayhan D, Ates L, Dilege S, Gulluoglu M, Tanju S, Kalayci G. Pulmonary large cell carcinoma with rhabdoid phenotype. Ann Diagn Pathol. 2005;9:223-6 pubmed
  • immunohistochemistry; human; 1:50
Berghmans T, Mascaux C, Martin B, Ninane V, Sculier J. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res. 2005;25:2385-9 pubmed
  • immunohistochemistry; human; 1:100
Akhan S, Yavuz E, Tecer A, Iyibozkurt C, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42 pubmed
  • immunohistochemistry; mouse; 1:100
  • western blot; mouse
Osada M, Nagakawa Y, Park H, Yamashita K, Wu G, Kim M, et al. p63-specific activation of the BPAG-1e promoter. J Invest Dermatol. 2005;125:52-60 pubmed
  • immunohistochemistry; human
Nemes J, Nemes Z, Marton I. p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2005;34:274-9 pubmed
  • immunohistochemistry; human
Uluoglu O, Akyurek N, Uner A, Coskun U, Ozdemir A, Gokcora N. Interdigitating dendritic cell tumor with breast and cervical lymph-node involvement: a case report and review of the literature. Virchows Arch. 2005;446:546-54 pubmed
  • immunohistochemistry; human
Aker F, Ozkara S, Eren P, Peker O, Armağan S, Hakan T. Cerebellar liponeurocytoma/lipidized medulloblastoma. J Neurooncol. 2005;71:53-9 pubmed
  • immunocytochemistry; human
Torkin R, Lavoie J, Kaplan D, Yeger H. Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther. 2005;4:1-11 pubmed
Lin J, Shen J, Yue H, Cao Z. miRNA‑183‑5p.1 promotes the migration and invasion of gastric cancer AGS cells by targeting TPM1. Oncol Rep. 2019;42:2371-2381 pubmed publisher
Shi L, Gehin T, Chevolot Y, Souteyrand E, Mangé A, Solassol J, et al. Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray. Anal Bioanal Chem. 2016;408:1497-506 pubmed publisher
Zhang Y, Zhou L, Rouge L, Phillips A, Lam C, Liu P, et al. Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nat Chem Biol. 2013;9:51-8 pubmed publisher
Li Z, Day C, Yang J, Tsai W, Lozano G, Shih H, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004;64:9080-5 pubmed
Sirianni N, Ha P, Oelke M, Califano J, Gooding W, Westra W, et al. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:6929-37 pubmed
Milne A, Carvalho R, van Rees B, van Lanschot J, Offerhaus G, Weterman M. Do collision tumors of the gastroesophageal junction exist? A molecular analysis. Am J Surg Pathol. 2004;28:1492-8 pubmed
Marchioni D, Monzani D, Rossi G, Rivasi F, Presutti L. Breast carcinoma metastases in paranasal sinuses, a rare occurrence mimicking a primary nasal malignancy. case report. Acta Otorhinolaryngol Ital. 2004;24:87-91 pubmed
Fomenkov A, Zangen R, Huang Y, Osada M, Guo Z, Fomenkov T, et al. RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2004;3:1285-95 pubmed
Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun D, Xiao Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004;64:5982-7 pubmed
Tulunay O, Gogus C, Baltaci S, Bulut S. Clear cell adenocarcinoma of the tunica vaginalis of the testis with an adjacent uterus-like tissue. Pathol Int. 2004;54:641-7 pubmed
Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller A, Caruso A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;24:6021-7 pubmed
Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol. 2004;14:96-102 pubmed
Ozkara S, Corakci A. Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression). Pathol Oncol Res. 2004;10:89-97 pubmed
Meert A, Martin B, Verdebout J, Paesmans M, Berghmans T, Ninane V, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer. 2004;44:295-301 pubmed
Jayasurya R, Francis G, Kannan S, Lekshminarayanan K, Nalinakumari K, Abraham T, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer. 2004;109:710-6 pubmed
Roberts K, Bhatia K, Stanton P, Lord R. Proteomic analysis of selected prognostic factors of breast cancer. Proteomics. 2004;4:784-92 pubmed
Deveci M, Deveci G. Altered distribution of metaplastic Paneth, gastrin and pancreatic acinar cells in atrophic gastritic mucosa with endocrine cell lesions. Tohoku J Exp Med. 2004;202:13-22 pubmed
Doglioni C, Piccinin S, Demontis S, Cangi M, Pecciarini L, Chiarelli C, et al. Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation. Am J Pathol. 2003;163:2277-87 pubmed
Alami J, Williams B, Yeger H. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer. 2003;107:365-74 pubmed
Schwartz J, Muscat J, Baker V, Larios E, Stephenson G, Guo W, et al. Oral cytology assessment by flow cytometry of DNA adducts, aneuploidy, proliferation and apoptosis shows differences between smokers and non-smokers. Oral Oncol. 2003;39:842-54 pubmed
Ko J, Lee Y, Hwang S, Lee Y, Shin S, Hwang J, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene. 2003;22:4679-89 pubmed
Kumpawat K, Deb S, Ray S, Chatterjee A. Genotoxic effect of raw betel-nut extract in relation to endogenous glutathione levels and its mechanism of action in mammalian cells. Mutat Res. 2003;538:1-12 pubmed
Mascaux C, Martin B, Verdebout J, Meert A, Ninane V, Sculier J. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J. 2003;21:753-8 pubmed
Campas C, Dalmau M, Montaner B, Barragan M, Bellosillo B, Colomer D, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia. 2003;17:746-50 pubmed
Campas C, Lopez J, Santidrian A, Barragan M, Bellosillo B, Colomer D, et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003;101:3674-80 pubmed
Kilicli Camur N, Kilicaslan I, Gulluoglu M, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int. 2002;52:463-9 pubmed
DiRenzo J, Signoretti S, Nakamura N, Rivera Gonzalez R, Sellers W, Loda M, et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002;62:89-98 pubmed
Lee H, Kim J, Ha S, Roh K, Seo E, Park W, et al. p53 gene mutations in Bowen's disease in Koreans: clustering in exon 5 and multiple mutations. Cancer Lett. 2000;158:27-33 pubmed
product information
Product Type :
Antibody
Product Name :
p53 Monoclonal Antibody (DO-7), Biotin
Catalog # :
MA5-12554
Quantity :
500 µL
Price :
US 456.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human
Applications :
Flow Cytometry: 0.5 µg/test, Immunocytochemistry: 1:20-1:200, Immunohistochemistry (Paraffin): 1:100-1:200, Immunoprecipitation: 1:50-1:100, Western Blot: 1:50-1:200
Species :
Human
Clone :
DO-7
Isotype :
IgG2b, kappa
Storage :
4° C
Description :
The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.
Immunogen :
Recombinant human wild-type p53 protein expressed in E. coli
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.5 µg/test, Immunocytochemistry: 1:20-1:200, Immunohistochemistry (Paraffin): 1:100-1:200, Immunoprecipitation: 1:50-1:100, Western Blot: 1:50-1:200
Aliases :
Antigen NY-CO-13; bbl; BCC7; bfy; bhy; cellular tumor antigen p53; Cys 51 Stop; EGK_08142; FLJ92943; HGNC11998; I79_002739; LFS1; Li-Fraumeni syndrome; mutant p53; mutant tumor protein 53; OTTMUSP00000006194; p44; p53; p53 cellular tumor antigen; p53 protein; p53 tumor suppressor; p53 tumor suppressor phosphoprotein; phosphoprotein p53; Tp53; tp53.L; transformation related protein 53; transformation-related protein 53; Trp248; Trp53; tumor protein 53; tumor protein p53; tumor protein p53 (Li-Fraumeni syndrome); tumor protein p53 L homeolog; tumor suppressor p53; tumor suppressor p53 phosphoprotein; tumor suppressor protein p53; tumor supressor p53; Tumour Protein p53; XELAEV_180196761mg; Xp53; Xrel3
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA